AzTrials
AzTrials

FibromyalgiaNCT06378788

Muscle Architecture and Muscle Strength in Fibromyalgia

An observational study of Fibromyalgia and Sarcopenia, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this observational study is to determine whether there is decrease in muscle mass and muscle strength in Fibromyalgia Syndrome (FMS) patients in comparison to controls. And to determine whether these parameters are correlated with clinical ones. Read more about this study

Who is it for?
Ages 18 to 65 years, women only
Conditions the study is for
Fibromyalgia, Sarcopenia, Muscle Weakness
What is being tested?
Demographic information form, widespread pain index (WPI) and symptom severity scale (SSS)
How many people
30 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Feb 2024to 30 Jun 2024
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Fisrt group: Fibromyalgia diagnosed patient group Second group: Healthy control group

Who may be able to join

  • Meeting the 2016 ACR (American College of Rheumatology) diagnostic criteria.
  • Diagnosed at least 1 year ago.

Who cannot join

  • Patients diagnosed with other rheumatological diseases, muscle diseases, or neuropathies.
  • Patients with a history of trauma affecting muscle morphology.
  • Patients engaging in regular exercise (at least 3-4 times a week for a minimum of 40 minutes).
  • Patients with uncontrolled comorbid diseases

Trial locations and contacts

1 site in 1 country.

Delal Ozturk, Res.Ass contact

+902124530453

drdelalozturk@gmail.com

Turkey (Türkiye)1 site, 1 recruiting
  • Bezmialem Vakif University

    Istanbul, Fatih, 34093

    Mehmet Serkan Kılıçoğlu, Ass.Prof., +902124530453, drserkankilicoglu@yahoo.com

    Delal Ozturk, Res.Ass., +902124530453, drdelalozturk@gmail.com

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Ultrasound-imaged Muscle Architecture and Muscle Strength in Fibromyalgia and it's Correlation With Pain, Disease Activity, and Functionality

The goal of this observational study is to determine whether there is decrease in muscle mass and muscle strength in Fibromyalgia Syndrome (FMS) patients in comparison to controls. And to determine whether these parameters are correlated with clinical ones. Briefly the main questions investigators aims to answer are:

  • Is there a significant difference in muscle morphology between FMS and controls?
  • Is there a significant difference in muscle strength between FMS and controls?
  • Is there a relationship between muscle thickness and pennation angle of the Quadriceps, gastrocnemius medialis, gastrocnemius lateralis and Tibialis anterior muscles and disease activity, pain and functionality?
  • Is there a correlation between muscle strength in FMS and disease activity, pain and functionality?
Read the detailed description

Fibromyalgia syndrome (FMS) was named by Smythe and Moldofsky when they defined tender points in 1970s. It is defined as chronic, generalized musculoskeletal pain accompanying with fatigue, sleep disturbance , cognitive and somatic disturbance. FMS has variable prevalence as %0,7-11 and usually affects middle aged women. It is second most common rheumatologic disease after osteoarthritis and thought to be the most common reason for musculoskeletal pain in middle aged women.

Recent studies have reported that both sarcopenia and decreased muscle strength occur in patients with chronic inflammatory diseases such as rheumatoid arthritis. There are concerns that sarcopenia may affect exercise tolerance, activities of daily living, and ultimately have a negative impact on cardiovascular fitness and physical and emotional well-being. On the other hand there is researches that support inflammation-driven pathways in the pathogenesis of fibromyalgia. Given the risk of pain related reduction in physical activity, patients are expected to have accelerated muscle wasting , decreased muscle strength and endurance and functionality.

However, there is no study that focused on muscle architecture and strength in FMS. This led us to design our study which will evaluate patients lower extremity muscles' thickness and pennation angles by ultrasound , most daily used muscles' strength by dynamometer, functionality by timed-up test and try to find whether there is a correlation between these parameters and patients' disease activity which will be determined with FMS specific scales.

Being tested
Demographic information form, widespread pain index (WPI), symptom severity scale (SSS), Fibromyalgia Impact Questionnaire (FIQ), Tender Point examination
Keywords
muscle strength, musculoskeletal ultrasound
Medical subject headings
Fibromyalgia, Sarcopenia, Muscle Weakness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Demographic information formOther

    aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.

  • widespread pain index (WPI)Diagnostic test

    The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:

    Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9.

  • symptom severity scale (SSS)Diagnostic test

    SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.

  • Fibromyalgia Impact Questionnaire (FIQ)Diagnostic test

    The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.

  • Tender Point examinationDiagnostic test

    Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.

  • Muscle Architecture visualized with ultrasoundOther

    The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.

  • Sarcopenia assessed by measuring isometric strengths of different parts of the bodyOther

    Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer

  • Timed Up & Go (TUG)Other

    The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.

Study groups in NCT06378788
Study groupRoleWhat they receive
FibromyalgiaPatients meeting the diagnostic criteria of 2016 American College of Rheumatology (ACR) guide for fibromyalgia
Receives: Other: Demographic information form; Diagnostic Test: widespread pain index (WPI); Diagnostic Test: symptom severity scale (SSS); Diagnostic Test: Fibromyalgia Impact Questionnaire (FIQ); Diagnostic Test: Tender Point examination; Other: Muscle Architecture visualized with ultrasound; Other: Sarcopenia assessed by measuring isometric strengths of different parts of the body; Other: Timed Up & Go (TUG)
Controlhealthy participants
Receives: Other: Demographic information form; Other: Muscle Architecture visualized with ultrasound; Other: Sarcopenia assessed by measuring isometric strengths of different parts of the body

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quadriceps Femoris Vastus Lateralis Muscle Thickness

    Vastus lateralis ultrasonography will be performed to evaluate muscle thickness.

    Measured: through study completion, an average of 16 weeks

  2. Quadriceps Femoris Vastus Lateralis Fascicle Length

    Vastus lateralis ultrasonography will be performed to evaluate fascicle length through measuring pennation angle (PA).

    Measured: through study completion, an average of 16 weeks

  3. Quadriceps Femoris Vastus Medialis Muscle Thickness

    Vastus Medialis ultrasonography will be performed to evaluate muscle thickness.

    Measured: through study completion, an average of 16 weeks

  4. Quadriceps Femoris Vastus Medialis Fascicle Length

    Vastus Medialis ultrasonography will be performed to evaluate fascicle length through measuring pennation angle (PA).

    Measured: through study completion, an average of 16 weeks

  5. Quadriceps Femoris Rectus Femoris Muscle Thickness

    Rectus Femoris ultrasonography will be performed to evaluate muscle thickness.

    Measured: through study completion, an average of 16 weeks

  6. Quadriceps Femoris Rectus Femoris Fascicle Length

    Rectus Femoris ultrasonography will be performed to evaluate fascicle length through measuring pennation angle (PA).

    Measured: through study completion, an average of 16 weeks

  7. Tibialis Anterior Muscle Thickness

    Tibialis Anterior ultrasonography will be performed to evaluate muscle thickness.

    Measured: through study completion, an average of 16 weeks

  8. Tibialis Anterior Muscle Fascicle Length

    Tibialis Anterior ultrasonography will be performed to evaluate fascicle length through measuring pennation angle (PA).

    Measured: through study completion, an average of 16 weeks

  9. Gastrocnemius Muscle Vastus Medialis Muscle Thickness

    Gastrocnemius muscle vastus medialis ultrasonography will be performed to evaluate muscle thickness.

    Measured: through study completion, an average of 16 weeks

  10. Gastrocnemius Muscle Vastus Medialis Fascicle Length

    Gastrocnemius muscle vastus medialis ultrasonography will be performed to evaluate fascicle length through measuring pennation angle (PA).

    Measured: through study completion, an average of 16 weeks

  11. Gastrocnemius Muscle Vastus Lateralis Muscle Thickness

    Gastrocnemius muscle vastus lateralis ultrasonography will be performed to evaluate muscle thickness.

    Measured: through study completion, an average of 16 weeks

  12. Gastrocnemius Muscle Vastus Lateralis Fascicle Length

    Gastrocnemius muscle vastus lateralis ultrasonography will be performed to evaluate fascicle length through measuring pennation angle (PA).

    Measured: through study completion, an average of 16 weeks

  13. Cervical Muscle strength

    Isometric Cervical Flexion (CF), Isometric Cervical Extension (CE) and Right and Left Isometric Cervical Lateral Flexion (CLF R/L) strengths will be calculated with hand-held dynamometer(Lafayette Manual Muscle Tester ) and reported as kilograms.

    Measured: through study completion, an average of 16 weeks

  14. Truncal Muscle strength

    Isometric Truncal flexion (TF)and Isometric Truncal extension (TE) strengths will be calculated with hand-held dynamometer(Lafayette Manual Muscle Tester ) and reported as kilograms.

    Measured: through study completion, an average of 16 weeks

  15. Shoulder Muscle strength

    Isometric Shoulder flexion (SF), Isometric Shoulder extension (SE), Isometric Shoulder abduction (SAB), Isometric Shoulder internal rotation (SIR) and Isometric Shoulder external rotation (SER) strengths will be calculated with hand-held dynamometer(Lafayette Manual Muscle Tester ) and reported as kilograms.

    Measured: through study completion, an average of 16 weeks

  16. Hip Muscle strength

    Isometric Hip flexion (HF), Isometric Hip extension (HE), Isometric Hip abduction (HAB), Isometric Hip internal rotation (HIR) and Isometric Hip external rotation (HER), strengths will be calculated with hand-held dynamometer(Lafayette Manual Muscle Tester ) and reported as kilograms.

    Measured: through study completion, an average of 16 weeks

  17. Knee Muscle strength

    Isometric Knee extension (KE) and Isometric Knee Flexion (KF) strengths will be calculated with hand-held dynamometer(Lafayette Manual Muscle Tester ) and reported as kilograms.

    Measured: through study completion, an average of 16 weeks

  18. Ankle Muscle strength

    Isometric Ankle Dorsiflexion (ADF) and Isometric Ankle Plantar flexion (APF) strengths will be calculated with hand-held dynamometer(Lafayette Manual Muscle Tester ) and reported as kilograms.

    Measured: through study completion, an average of 16 weeks

  19. Timed Up & Go (TUG)

    The patient sits in the chair with his/her back against the chair back. On the command "go," the patient rises from the chair, walks 3 meters at a comfortable and safe pace, turns, walks back to the chair and sits down.

    Timing begins at the instruction "go" and stops when the patient is seated and will be reported by seconds.

    This test aim to determine patients functional state and mobility .

    Measured: through study completion, an average of 16 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2024
  2. Study start1 Feb 2024
  3. Primary completion30 Apr 2024 (estimated)
  4. Study completion30 Jun 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
30 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT06378788
Sponsor's protocol ID
2023/211
Status last verified
Apr 2024
First submitted
4 Apr 2024
Last updated
25 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Privacy reasons

Publications

  • Gyorfi M, Rupp A, Abd-Elsayed A. Fibromyalgia Pathophysiology. Biomedicines. 2022 Nov 29;10(12):3070. doi: 10.3390/biomedicines10123070.

    PubMed 36551826
  • Blanco I, Beritze N, Arguelles M, Carcaba V, Fernandez F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernandez-Bustillo E, Hollenberg MD. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol. 2010 Dec;29(12):1403-12. doi: 10.1007/s10067-010-1474-7. Epub 2010 Apr 30.

    PubMed 20428906
  • Ruggiero L, Manganelli F, Santoro L. Muscle pain syndromes and fibromyalgia: the role of muscle biopsy. Curr Opin Support Palliat Care. 2018 Sep;12(3):382-387. doi: 10.1097/SPC.0000000000000355.

    PubMed 29912728
  • Chinn S, Caldwell W, Gritsenko K. Fibromyalgia Pathogenesis and Treatment Options Update. Curr Pain Headache Rep. 2016 Apr;20(4):25. doi: 10.1007/s11916-016-0556-x.

    PubMed 26922414
  • Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol. 1986;15(2):165-73. doi: 10.3109/03009748609102084.

    PubMed 3462905
  • Thieme K, Rose U, Pinkpank T, Spies C, Turk DC, Flor H. Psychophysiological responses in patients with fibromyalgia syndrome. J Psychosom Res. 2006 Nov;61(5):671-9. doi: 10.1016/j.jpsychores.2006.07.004.

    PubMed 17084146
  • Zetterman T, Markkula R, Partanen JV, Miettinen T, Estlander AM, Kalso E. Muscle activity and acute stress in fibromyalgia. BMC Musculoskelet Disord. 2021 Feb 14;22(1):183. doi: 10.1186/s12891-021-04013-1.

    PubMed 33583408
  • Larsson A, Palstam A, Bjersing J, Lofgren M, Ernberg M, Kosek E, Gerdle B, Mannerkorpi K. Controlled, cross-sectional, multi-center study of physical capacity and associated factors in women with fibromyalgia. BMC Musculoskelet Disord. 2018 Apr 19;19(1):121. doi: 10.1186/s12891-018-2047-1.

    PubMed 29673356
  • Cigaran-Mendez M, Ubeda-D'Ocasar E, Arias-Buria JL, Fernandez-de-Las-Penas C, Gallego-Sendarrubias GM, Valera-Calero JA. The hand grip force test as a measure of physical function in women with fibromyalgia. Sci Rep. 2022 Mar 1;12(1):3414. doi: 10.1038/s41598-022-07480-1.

    PubMed 35233066
  • Kuzu O, Aras B. Sonographic measurement of the neck extensor muscle thickness in patients with fibromyalgia. Musculoskelet Sci Pract. 2022 Jun;59:102541. doi: 10.1016/j.msksp.2022.102541. Epub 2022 Feb 26.

    PubMed 35240562
  • Blazevich AJ, Gill ND, Zhou S. Intra- and intermuscular variation in human quadriceps femoris architecture assessed in vivo. J Anat. 2006 Sep;209(3):289-310. doi: 10.1111/j.1469-7580.2006.00619.x.

    PubMed 16928199
  • Yurdakul OV, Ince OE, Bagcier F, Kara M, Kultur E, Aydin T. Evaluating the strength of spinal and proximal girdle muscles in patients with axial spondyloarthritis: Correlation with activity, disability, and functionality. Int J Rheum Dis. 2021 May;24(5):701-710. doi: 10.1111/1756-185X.14102. Epub 2021 Mar 22.

    PubMed 33750032

Questions about this trial

What is this clinical trial studying?

An observational study of Fibromyalgia and Sarcopenia, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Delal Ozturk, Res.Ass (+902124530453, drdelalozturk@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quadriceps Femoris Vastus Lateralis Muscle Thickness (time frame: through study completion, an average of 16 weeks). The study lists 19 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06378788, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in